Literature DB >> 35900474

Relationship between patterns of cannabis use and functional and symptomatic trajectories in first-episode psychosis.

Abigail C Wright1,2, Julia Browne3,4,5, Corinne Cather3,4, Piper Meyer-Kalos6, Kim T Mueser7.   

Abstract

Cannabis use is common in first-episode psychosis (FEP) but evidence is mixed about the extent to which cannabis use predicts symptoms and functional outcomes among those who seek treatment. This study sought to characterize cannabis use patterns and examine the relationship with clinical outcomes, including interactions with early intervention services (EIS). Data were drawn from the Recovery After an Initial Schizophrenia Episode-Early Treatment Program (RAISE-ETP) study including FEP individuals receiving treatment at sites randomized to provide either EIS (NAVIGATE) or community care (CC). Cannabis use was assessed monthly and symptom and functioning data were collected at baseline, 6, 12, 18, and 24 months. Among the 404 participants enrolled, 334 were classified into four cannabis use groups (consistent, sporadic, stopped, and never users) based on their use during the first year. Consistent and sporadic cannabis users were younger, whereas those who had stopped using were older. Sporadic users had the highest depression and the lowest functioning at baseline and improved less during treatment in negative emotions and intrapsychic foundations (e.g., motivation and sense of purpose) than non-users. However, sporadic users who received NAVIGATE improved more in overall symptoms and functioning than those who received CC. Consistent users did not tend to differ in their trajectories from non-users. Individuals with FEP who use cannabis sporadically showed less clinical improvement than non-users. However, EIS treatment reduced the negative effects of sporadic cannabis use on clinical outcomes. Those who use cannabis sporadically may have unique needs that require attention in EIS.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Coordinated specialty care; Early intervention; Outcomes; Substance use; Trajectories; Treatment

Year:  2022        PMID: 35900474     DOI: 10.1007/s00406-022-01441-5

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.760


  42 in total

1.  Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis.

Authors:  Michael T Compton; Beth Broussard; Claire E Ramsay; Tarianna Stewart
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

2.  Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: Data from the national RAISE-ETP study.

Authors:  Oladunni Oluwoye; Maria Monroe-DeVita; Ekaterina Burduli; Lydia Chwastiak; Sterling McPherson; Jon M McClellan; Michael G McDonell
Journal:  Early Interv Psychiatry       Date:  2018-01-22       Impact factor: 2.732

3.  Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates, and subgroups.

Authors:  K T Mueser; P R Yarnold; S D Rosenberg; C Swett; K M Miles; D Hill
Journal:  Schizophr Bull       Date:  2000       Impact factor: 9.306

Review 4.  Cannabis use and earlier onset of psychosis: a systematic meta-analysis.

Authors:  Matthew Large; Swapnil Sharma; Michael T Compton; Tim Slade; Olav Nielssen
Journal:  Arch Gen Psychiatry       Date:  2011-02-07

5.  Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort.

Authors:  E Manrique-Garcia; S Zammit; C Dalman; T Hemmingsson; S Andreasson; P Allebeck
Journal:  Psychol Med       Date:  2011-10-17       Impact factor: 7.723

6.  The impact of substance use at psychosis onset on First Episode Psychosis course: results from a 1 year follow-up study in Bologna.

Authors:  Ilaria Tarricone; Jane Boydell; Serena Panigada; Fabio Allegri; Thomas Marcacci; Maria Gabriella Minenna; Arnisa Kokona; Federico Triolo; Viviana Storbini; Rossella Michetti; Craig Morgan; Marta Di Forti; Robin M Murray; Domenico Berardi
Journal:  Schizophr Res       Date:  2014-02-11       Impact factor: 4.939

7.  Diagnostic and demographic correlates of substance abuse in schizophrenia and major affective disorder.

Authors:  K T Mueser; P R Yarnold; A S Bellack
Journal:  Acta Psychiatr Scand       Date:  1992-01       Impact factor: 6.392

Review 8.  Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use.

Authors:  Hannah Myles; Nicholas Myles; Matthew Large
Journal:  Aust N Z J Psychiatry       Date:  2015-08-18       Impact factor: 5.744

9.  The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study.

Authors:  Louisa Degenhardt; Chris Tennant; Stuart Gilmour; David Schofield; Louise Nash; Wayne Hall; Diana McKay
Journal:  Psychol Med       Date:  2007-02-09       Impact factor: 7.723

Review 10.  Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis.

Authors:  Tabea Schoeler; Anna Monk; Musa B Sami; Ewa Klamerus; Enrico Foglia; Ruth Brown; Giulia Camuri; A Carlo Altamura; Robin Murray; Sagnik Bhattacharyya
Journal:  Lancet Psychiatry       Date:  2016-01-15       Impact factor: 27.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.